Scotiabank raised the firm’s price target on Argenx to $416 from $408 and keeps a Sector Perform rating on the shares. The firm believes the FDA approval of subQ efgart for the treatment of chronic inflammatory demyelinating polyneuropathy was largely anticipated by investors and supports the utility of this agent, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- argenx Unveils Innovative CIDP Treatment VYVGART Hytrulo
- argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
- Argenx announces FDA approval of VYVGART Hytrulo
- Argenx Unveils ‘Vision 2030’ for Transforming Autoimmunity
- argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024